Emtricitabine Capsule shortage
Emtricitabine Capsule is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.
Gilead Sciences is stopping its emtricitabine 200 mg capsules, and this change may be permanent. Other makers — Aurobindo and Cipla USA — still list the same medicine, so supply may be available through them.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Emtricitabine Capsule. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 17, 2026Currently in shortage1 of 1 product affected.
-
Jun 17, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Emtriva, Capsule, 200 mg (NDC 61958-0601-1) | — | — | Product expected to be available until March 2027 | — |
These rows are manufacturer reports to the FDA for Emtricitabine Capsule — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Emtricitabine Capsule? options further down this page.
Why is Emtricitabine Capsule in shortage?
Gilead Sciences has reported to the FDA that their brand-name version of this medication, Emtriva (emtricitabine 200 mg capsules), is going to be permanently discontinued. The good news is that it's not going away right away — Gilead expects this specific product to remain available until March 2027, so there's still some time before supply runs out.
It's worth knowing that Gilead did not share a specific public reason for why they are stopping this particular product. This report covers only Gilead's version of emtricitabine 200 mg capsules, so it doesn't necessarily mean every form of this medication from every manufacturer is affected.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Emtricitabine Capsule, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Emtricitabine Capsule?
Emtricitabine 200 mg capsules are currently on the FDA drug-shortage list, and the record notes this product is being discontinued.
The only strength listed here, 200 mg, has no available source reported at this time. The manufacturer on this record, Gilead Sciences (Emtriva), reports that its supply is expected to last until March 2027. Because the product is marked "to be discontinued," this supply change may be permanent, so a conversation with your prescriber is the right next step to plan ahead.
Please keep taking your medicine as prescribed while this is sorted out. Here is how to approach it:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers for the 200 mg capsule — local stock can differ from national reports.
- The same medicine, emtricitabine 200 mg capsules, is also listed from Aurobindo Pharma and Cipla USA. Your pharmacy may be able to source one of these, though it may not be on the shelf right away.
- If your exact capsule cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Emtricitabine Capsule?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Emtricitabine Capsule is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Emtricitabine | EMTRICITABINE 200 mg/1 | Capsule | Aurobindo Pharma Limited | 65862-0301-05 |
| Emtricitabine | EMTRICITABINE 200 mg/1 | Capsule · Oral | Cipla USA Inc. | 69097-0642-02 |
Alternative dosage forms of Emtricitabine
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| emtricitabine 200 mg | Cipla | 30 capsules | $12.486 | AB | Availability likely |
| Emtriva 200 mg | Gilead | 30 capsules | $17.446 | AB | Availability likely |
| Emtricitabine 200 mg | Aurobindo | 500 capsules | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Emtricitabine Capsule — that fall in the same broad treatment class (antivirals, hiv-specific, nucleoside analog, rti) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Emtricitabine Capsule shortage FAQs
Is Emtricitabine Capsule in shortage?
Which products are affected?
When will Emtricitabine Capsule be available again?
Can I still get Emtricitabine somewhere?
What should I do if I take Emtricitabine Capsule?
Still have a question about the Emtricitabine Capsule shortage?
Ask a pharmacist about this shortage →View Emtricitabine Capsule on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.